1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.1.1 Psychiatry and Mental Health Group

Publications: 52 | Q1:39

COMPOSITION

Celso Arango López.
Jefe del Departamento Psiquiatría del Niño y del Adolescente. Hospital Universitario La Pazadrid

- **María Fe Bravo Ortíz.** *Profesora Honoraria. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Pablo Aguirre Morán.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Teresa Alonso Poza.** *Investigadora Predoctoral. FIBHULP*
- **Jorge Andreo Jover.** *Investigador Predoctoral. FIBHULP*
- **Carmen Bayón Pérez.** *Jefa de sección Hospital de Día Adultos. Hospital Universitario La Paz; Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Laura Caraballo Romero.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Diego Carracedo Sanchidrián.** *Facultativo Especialista en Psicología Clínica. Hospital Universitario La Paz*
- **Susana Cebolla Lorenzo.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Javier Curto Ramos.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **María Jesús de la Iglesia Mansilla.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Eduardo Fernández Jiménez.** *Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Omar Ariel Gaona Casas.** *Investigador Predoctoral. FIBHULP*
- **Ignacio García Cabeza.** *Jefe de Servicio de Psiquiatría. Hospital Dr. Rodríguez Lafora*
- **Blanca García Vázquez.** *Facultativa Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Jessica Garrido Boltón.** *Facultativa Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Nieves González Suárez.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Paula Herrero Ortega.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Eduardo Jiménez Sola .** *Facultativo Especialista de Área en Psiquiatría . Hospital Universitario La Paz*
- **Jesús Martí Esquitino.** *Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Gonzalo Martínez-Ales García.** *Psiquiatra e Investigador. Icahn School of Medicine at Mount Sinai*
- **Convadonga Martínez Díaz-Caneja.** *Facultativo Especialista de Área en Psiquiatría. FIBHULP*
- **María del Carmen Moreno Ruiz.** *Jefa de Sección de Psiquiatría del Niño y del Adolescente. Hospital Universitario La Paz*
- **Ainoa Muñoz San José.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Patricia Nieva Tejado.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Luis Nocete Navarro.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz. Consejería de Sanidad CM*
- **Alberto Oliva Lozano.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Óscar Pajares González-Gallego.** *Enfermero Especialista en Salud Mental CSM Fuencarral. Hospital Universitario La Paz*
- **Ángela Palao Tarrero.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Irene Pérez de Ciriza Galarza.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Pau Pérez Sales.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Rosa Villanueva Peña.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

STRATEGIC OBJETIVES

- The group focuses its objectives on evaluating the effectiveness of psychotherapeutic techniques as part of the treatment for mental disorders and other medical conditions.
- Their main areas of research are: research into severe mental illness (first-episode psychosis and bipolar disorder), suicide prevention, and other medical conditions such as cancer and chronic pain, as well as the psychological and social impact of the Covid-19 pandemic, and transplants in children. They participate in clinical trials on new treatments and specific therapies to improve the prognosis for these disorders.
- It also focuses on researching the interaction of genetic and environmental factors in the etiology and evolution of mental disorders, especially psychosis.
- We are especially focused on evaluating the efficacy and effectiveness of third-generation psychotherapies, including mindfulness, and other low-intensity psychological interventions.
- In addition, the group is involved in the evaluation of new treatments or new indications in mental illnesses through participation in clinical trials."

RESEARCH LINES

- Psychotherapeutic interventions in mental disorders
- Suicide prevention
- Psychological and social impact of the COVID-19 pandemic
- Online health interventions
- Mindfulness-based interventions
- Environment/gene interaction in the first episode of psychosis
- Impact on the mental health of children and adolescents undergoing transplantation

RESEARCH ACTIVITY

Doctoral Theses

- **Carracedo Sanchidrián D.** *Terapia Cognitiva Basada en Mindfulness frente a Intervención Psicoeducativa en Pacientes con Trastorno Bipolar con Síntomas Subsindrómicos Depresivos: Estudio Controlado Aleatorizado [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(14/10/2024). Director: Dios Perrino C, Lahera Forteza G*
- **Hernández Santillán GA.** *Prevalencia y factores asociados a síntomas depresivos en madres y padres en los seis primeros meses postparto y alteración del vínculo materno-infantil. UAM (18/07/2025). Directoras: María Fe Bravo Ortiz, Margarita Alcamí Pertejo*

Publications

- **Addington J, Liu L, Chu M, Jungert K, Penzel N, Pasternak O, Farina E, Carrion RE, Corcoran CM, Mittal VA, Strauss GP, Yung AR, Alameda L, Arango C, Borders O, Bouix S, Breitborde NJK, Broome MR, Cadenhead KS, Castillo-Passi R, Chen EYH, Choi J, Coleman MJ, Conus P, Díaz-Caneja CM, Ellman LM, Poli PF, Gaspar PA, Gerber C, Glenthoj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Kapur T, Kelly S, Kerr MJ, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Marcy PJ, Mathalon DH, Mourgues C, Nordentoft M, Nunez AR, Pearlson GD, Pérez J, Perkins DO, Powers AR, Rogers J, Sabb FW, Schiffman J, Seitz-Holland J, Shah JL, Silverstein SM, Smesny S, Stone WS, Thompson JL, Upthegrove R, Verma S, Wang JJ, Wolf DH, Zhang TH, Addamo L, Buccilli K, Dwyer D, Todd S, Cho YT, Fontenau C, Tamayo Z, Bearden CE, Kane JM, McGorry PD, Kahn RS, Shenton ME, Woods SW, Nelson B, Calkins ME.** *Baseline clinical characterization of participants in the accelerating medicines partnership schizophrenia program. Schizophr Bull Open. 2025; 6(1): sgaf012. Article. IF: 2.4; Q3*
- **Addington J, Shalev A, Liu L, Jahraus C, Chu MNC, Farina E, Poli PF, Marcy PJ, Nunez AR, Calkins ME, Alameda L, Arango C, Borders O, Bouix S, Breitborde NJK, Broome MR, Cadenhead KS, Carrion RE, Castillo-Passi R, Chen EYH, Choi J, Coleman MJ, Conus P, Corcoran CM, Díaz-Caneja CM, Ellman LM, Gaspar PA, Gerber C, Glenthoj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Kapur T, Kelly S, Kerr MJ, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Mathalon DH, Mittal VA, Mourgues C, Nordentoft M, Pasternak O, Pearlson GD, Penzel N, Pérez J, Perkins DO, Powers AR, Rogers J, Sabb FW, Schiffman J, Seitz-Holland J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Thompson JL, Upthegrove R, Verma S, Wang JJ, Wolf DH, Yung AR, Zhang TH, Addamo L, Buccilli K, Todd S, Dwyer D, Bearden CE, Kane JM, Mcgorry PD, Kahn RS, Shenton ME, Woods SW, Nelson B.** *Sample ascertainment and recruitment sources in the accelerating medicines partnership schizophrenia program. Schizophr Bull Open. 2025; 6(1): sgaf013. Article. IF: 2.4; Q3*
- **Andrés-Camazón P, Díaz-Caneja CM, Ballem R, Chen JY, Calhoun VD, Iraji A.** *Neurobiology-based cognitive biotypes using multi-scale intrinsic connectivity networks in psychotic disorders. Schizophrenia (Heidelb). 2025; 11(1): 45. Article. IF: 4.5; Q1*
- **Arango C, Baeza I, García-Rizo C, Crespo-Facorro B, Lahera G, Vieta E, Becker F, Dwyer G, Bourke S, Gibson AEJ, Gabarda-Inat I, Álvarez-Barón E.** *Exploring the impact of schizophrenia and its pharmacological treatment on health-related quality of life and treatment preferences. Patient Prefer Adher. 2025; 19: 2647-61. Article. IF: 2.6; Q2*
- **Arango C, Fiorillo A, Dom G, López-Morinigo JD.** *Responsiveness of European countries to the population mental health needs: A cross-national comparison study. Eur Psychiat. 2025; 68(1): e102. Article. IF: 7.9; D1*
- **Arango C, Vieta E.** *Cibersam: A change in the paradigm of mental health research in Spain. Span J Psychiatry Ment Health. 2025; 18(1): 3-5. Editorial Material. IF: 2.6; Q2*
- **Arregui-Gallego B, Orts-Cortés MI, Moreno-Casbas MT, Abad-Corpa E, Camacho-Bejarano R, Cidoncha-Moreno MA, Feria-Raposo I, Iruzubieta-Barragán J, Carmona M, Cristóbal-Domínguez E, Bernués-Caudillo L, Casado-Ramírez E, Recas-Martin A, Sánchez-López D, Company-Sancho MC, Rascón NL, Esteban-Sepúlveda S, Vidal-Thomàs MC, Alonso I, Muñoz-Jiménez D, Segura-Heras JV, Moncho J, Rich-Ruiz M.** *Factors modulating the impact of the COVID-19 pandemic on posttraumatic stress symptomatology of the Spanish healthcare workers: A cohort study. Plos One. 2025; 20(6): e0323777. Article. IF: 2.8; Q2*
- **Asgari-Targhi A, Yao BE, Brown L, García S, Nagendra A, Chin K, Billah T, Penzel N, John O, Prunier N, Veale S, Kotler E, Jacobs GR, Zhan M, Coleman MJ, Bouix S, Pasternak O, Cecci G, Baker JT, Mathalon DH, Kelly SM, Corcoran CM, Reichenberg A, Rossum IWV, Kubicki M, Spark J, Dwyer D, Arango C, Fusar-Poli P, Calkins M, Shah JL, Mittal V, Thompson A,**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

McGorry PD, Kahn RS, Kane JM, Bearden CE, Woods SW, Nelson B, Shenton ME, Staglin B, Larrauri CA, Lewandowski KE, Kapur T. *Bridging Science and Hope: integrating and communicating lived experience in accelerating medicines partnership® schizophrenia program. Schizophrenia (Heidelb). 2025; 11(1): 57. Editorial Material. IF: 4.5; Q1*

- **Aymerich C, Pedruzo B, de Pablo GS, Labad J, McCutcheon R, Pillinger T, González-Torres MA, Sanchez-Gistau V, Oliver D, Alonso-Alconada D, Navalón P, Sugranyes G, Vieta E, Arango C, McGuire P, Fusar-Poli P, Catalan A.** *Do biological alterations precede the onset of psychosis? A systematic review and meta-analysis of immune, cardiometabolic, prolactin and HPA axis alterations in clinical high-risk for psychosis. Brain Behav Immun. 2025; 128: 219-33. Article. IF: 7.5; D1*
- **Basic D, Czepiel D, Hoek HW, Martínez AM, Mccormack C, Susser ES, Mascayano F, Moro MF, Carta MG, Martínez-Alés G, Fernández-Jiménez E, Barathie JA, Karam EG, Nishi D, Asaoka H, Ayinde O, Gureje O, Afolabi O, Olaopa O, Ramírez J, Basagoitia A, Soto MTS, Durand-Arias S, Seblová J, Seblova D, Tenorio A, Ballester D, Burrone MS, Alvarado R, Santaella-Tenorio J, Ouali U, Isahakyan A, Lindert J, Sapag JC, Ramírez DE, Alnasser L, Rivera-Segarra E, Balalian A, Mediavilla R, van der Ven E.** *Trusting in times of the COVID-19 crisis: Workplace and government trust and depressive symptoms among healthcare workers. Glob Ment Health (Camb). 2025; 12: e130. Article. IF: 3.4; Q2*
- **Bernardo M, Marsá MD, González-Pinto A, Carrasco MM, Sola VP, Sáiz PA, Vieta E, Torrens M, Arango C, Crespo-Facorro B.** *Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel. Neurol Ther. 2025; 14(1): 85-98. Review. IF: 4.7; Q1*
- **Bioque M, Llorca-Bofi V, MacDowell KS, Amoretti S, Mezquida G, Cuesta MJ, Díaz-Caneja CM, Ibáñez A, Segarra R, González-Pinto A, Roldán A, Sáiz PA, Mané A, Lobo A, Martínez-Pinteño A, Cano-Escalera G, Berrocoso E, Bernardo M.** *Impact of relapse in BDNF receptors expression in patients with a first episode of schizophrenia. Schizophrenia Bull. 2025; 51(5): 1339-50. Article. IF: 5.7; Q1*
- **Cortese S, Moreno C.** *Advancing the evidence base for child and adolescent psychopharmacology. Bmj Ment Health. 2025; 28(1): e301634. Editorial Material. IF: 6.6; D1*
- **de la Serna E, Moreno D, Sugranyes G, Camprodon-Boadas P, Ilzarbe D, Bigorra A, Mora-Maltas B, Baeza I, Flamarique I, Parrilla S, Díaz-Caneja CM, Moreno C, Borras R, Torrent C, García-Rizo C, Castro-Fornieles J.** *Effects of parental characteristics on the risk of psychopathology in offspring: a 4-year follow-up study. Eur Child Adoles Psy. 2025; 34(10): 3035-45. Article. IF: 4.4; Q1*
- **de Pablo GS, Pérez-Rodríguez V, Olivares JD, Camacho-Rubio J, Sharma A, Catalán A, Breedvelt J, Aymerich C, Pop M, Moreno C, Kelleher I, Anderson J, Fusar-Poli P, Correll CU, Young AH.** *Development and predictors of bipolar disorder in children and adolescents with depressive disorders: a systematic review, meta-analysis, and meta-regression. Eur Psychiat. 2025; 68(1): e16. Review. IF: 7.9; D1*
- **Demjaha A, Stahl D, Arango C, Glenthoj B, Rodríguez-Jiménez R, Díaz-Caneja CM, Baandrup L, Ebdrup B, García-Portlla MP, Díaz-Marsa M, Winter-van Rossum I, Kahn R, Dazzan P, McGuire P.** *Confirmatory factor analysis of competing PANSS negative symptom models: data from OPTiMiSE first-episode schizophrenia study. Bjpsych Open . 2025; 12(1): e12. Article. IF: 4.0; Q1*
- **Dickson SL, Tracey I, Cirulli F, Kas MJH, Konradsson-Geuken Å, Rostasy K, Kestens E, Arango C, Mohr P, Balazs J, Simon J, Weemaes K, Boselli S, Hall J, Asakawa T, Quoidbach V.** *Prioritizing brain health in youth: bringing neuroscience to society and informing policy, lessons learnt from the european brain council expert meeting held at the Federation of European Neuroscience Societies Forum 2024. Eur J Neurosci. 2025; 61(2): e16680. Editorial Material. IF: 2.5; Q3*
- **Domínguez-Alonso S, Tubio-Fungueiriño M, González-Peñas J, Fernández-Prieto M, Parellada M, Arango C, Carracedo A, Rodríguez-Fontenla C.** *Alternative splicing analysis in a Spanish ASD (Autism Spectrum Disorders) cohort: in silico prediction and characterization. Sci Rep-Uk. 2025; 15(1): 10730. Article. IF: 4.9; Q1*
- **Ecker C, Pretzsch CM, Leyhausen J, Berg LM, Gurr C, Seelemeyer H, McAlonan G, Puts NA, Loth E, Dell'Aqua F, Mason L, Charman T, Oakley B, Bourgeron T, Beckmann C, Buitelaar JK, Arango C, Banaschewski T, Chiocchetti AG, Freitag CM, Hattingen E, Krueger-Burg D, Schmeisser MJ, Repple J, Reif A, Murphy DG.** *Transcriptomic decoding of surface-based imaging phenotypes and its application to pharmacotranscriptomics. Nat Commun. 2025; 16(1): 6727. Article. IF: 18.1; D1*
- **Ferraro L, Di Forti M, La Barbera D, La Cascia C, Morgan C, Tripoli G, Jongsma H, Seminerio F, Sartorio C, Sideli L, Tarricone I, Carloni AL, Szoke A, Pignon B, Bernardo M, de Haan L, Arango C, Velthorst E, Gayer-Anderson C, Kirkbride J, Rutten BPF, Lasalvia A, Tosato S, Del Ben CM, Menezes PR, Bobes J, Arrojo M, Tortelli A, Jones P, Selten JP, van Os J, Murray R, Quattrone D, Vassos E.** *Cognitive presentation at psychosis onset through premorbid deterioration and exposure to environmental risk factors. Psychol Med. 2025; 55: e12. Article. IF: 5.2; Q1*
- **Galvañ J, Suárez-Campayo J, Ayora M, Gil S, Rossum IWV, Berger G, Leucht S, Kahn RS, Arango C, Díaz-Caneja CM.** *Extrapyramidal symptoms as early clinical predictors in first-episode schizophrenia and schizophreniform disorder: findings from the OPTiMiSE trial. Eur Neuropsychopharm. 2025; 98: 35-45. Article. IF: 8.1; D1*
- **García-Vázquez B, Muñoz-Sanjosé A, Fernández-López A, Pérez-de-Ciriza I, Nocete-Navarro L, Almaraz-Garzón E, Martín-Palacios MT, Novella B, Bravo-Ortiz MF, Ayuso-Mateos JL, Bayón C, Mediavilla R.** *A stress-reduction eHealth intervention for healthcare workers in primary care settings: an implementation study. Front Public Health. 2025; 13: 1600059. Article. IF: 4.1; Q1*
- **Gárriz-Luis A, Rodríguez-Toscano E, Burdeus-Olavarrieta M, Arango C, Parellada M, Díaz-Caneja CM.** *Clinical and neuropsychological characterization of Jacobsen syndrome (del11q). J Neurodev Disord. 2025; 18(1): 4. Article. IF: 3.6; Q2*
- **González-Ortega I, Díaz-Marsa M, López-Peña P, Fernández-Sevillano J, Andreo-Jover J, Bobes J, Bravo-Ortiz MF, Cebria AI, Crespo-Facorro B, de la Torre-luque A, Elices M, Fernández-Rodrigues V, Garrido-Torres N, Grande I, Palao-Tarrero A, Pemau A, Roberto N, Ruiz-Veguilla M, Seijo-Zazo E, Alberich S, González-Pinto A, Pérez V.** *Clinical predictors and psychosocial risk factors of suicide attempt severity. Span J Psychiatry Ment Health. 2025; 18(3): 182-90. Article. IF: 2.6; Q2*
- **Gorwood P, Yildirim M, Madera-McDonough J, Fagiolini A, Arango C, Correll CU, Arcà E, Barlassina A, Selveindran S, Sahota N, Kane JM.** *Assessment of functional recovery in patients with schizophrenia, with a focus on early-phase disease: results from a Delphi consensus and narrative review. Bmc Psychiatry. 2025; 25(1): 398. Article. IF: 4.6; Q1*
- **Howes OD, Bukala BR, Chen EYH, Correll CU, Hasan A, Honer WG, Kane JM, Leucht S, Siafis S, Agid O, Akena D, Arango C, Atwoli L, Barnes TRE, Birnbaum ML, Bitter I, Breier A, Buchanan RW, Citrome L, Cotter DR, Crossley N, Davidson M, De Bartolomeis A, Delisi LE, Dollfus S, Dursun SM, Ebdrup BH, Elkis H, Emsley R, Falkai P, Fernández-Egea E, Fleischhacker W, Freudenreich O, Gadelha A, Gaebel W, Graff-Guerrero A, Gridley A, Hallak JEC, Homan P, Kahn RS, Kaiser S, Kapi M, Kennedy JL, Kim E, Kinon BJ, Kwon JS, Lawrie SM, Lee J, Leweke FM, Li T, Libiger J, Marder SR, Melle I, Meltzer H, Mucci A, Naber D, Nakajima S, Nielsen J, O'Brien O, Ojagbemi A, Omlor W, Pantelis C, Peuskens J, Raedler TJ, Ran MS, Marques TR, Remington G, Rossell S, Rubio JM, Sachs G, Scott J, Si TM, Siskind D, Siu CO, Sommer IE, Suzuki T, Takeuchi H, Tandon R, Taylor D, Teferra S, Thomas N, Tiihonen J, Uchida H, Ucok A, Umbricht D, Venkatasubramanian**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

G, Wagner E, Walters JTR, Wang CY, Weiser M, Wright C, Yu X, McCutcheon RA. *Relapse in schizophrenia: a systematic review of criteria for clinical studies and international consensus guidelines to improve them. Am J Psychiat. 2025; 182(11): 969-83. Review. IF: 15.9; D1*

- **Janssen J, Gallego AG, Díaz-Caneja CM, Lois NG, Janssen N, González-Peñas J, Gordaliza PM, Buimer E, van Haren N, Arango C, Kahn R, Pol HEH, Schnack HG.** *Heterogeneity of morphometric similarity networks in health and schizophrenia. Schizophrenia (Heidelb). 2025; 11(1): 70. Article. IF: 4.5; Q1*
- **Kuzman MR, Nordentoft M, Raballo A, Mohr P, Fiorillo A, Dom G, Mihajlovic G, Jendricko T, Chumakov E, Barjaktarov S, Carpiniello B, Patarák M, Martin L, Dudek D, Samochowiec J, Taube M, Courtet P, Babic D, Racetovic G, Catthoor K, Arango C, Maruta N, Basar K, Vahip S, Szekeres G, Lien LR, Popova A, Zhelev R, Jääskeläinen E, Delic M, Chkonia E, Chichai J, Telles-Correia D, Cosman DCM, Beezhold J, Falkai P.** *Schizophrenia treatment preferences of psychiatrists versus guidelines: A European perspective. Eur Psychiat. 2025; 68(1): e107. Review. IF: 7.9; D1*
- **Lefaucheur JP, Colzi C, Hollander E, Pampaloni I, Van Ameringen M, Baeken C, Fusar-Poli P, Arango C, Fontenelle LF, Batail JM, Brunoni AR, Nicolini H, Haffen E, Soriano-Mas C, Rodríguez CI, Dell'Osso BM, Vieta E, Sauvaget A, Szekely D, Mayer-Linderberg A, Denys D, Stein DJ, Drapier D, Voon V, Pallanti S.** *Comparison between accelerated and standard or sham rTMS in the treatment of depression: A systematic review. Neurosci Biobehav R. 2025; 173: 106140. Article. IF: 8.5; Q1*
- **Leppanen J, Kieseppä V, Eskelinen S, Säynäjäkangas V, Rutten B, Gülöksüz S, Halt AH, Riipinen P, Díaz-Caneja CM, Kelleher I.** *Clinical predictors of readmission to psychiatric inpatient care: A 20-year follow up study of former adolescent inpatients. Psychiat Res. 2025; 351: 116606. Article. IF: 5.1; Q1*
- **Llorca-Bofí V, Garriga M, Mezquida G, García-Rizo C, Vieta E, Díaz-Caneja CM, Bernardo M, Madero S, Pina-Camacho L, Cuesta MJ, Bergé D, Baeza I, Bioque M, Amoretti S.** *Comparing PANSS-6 and PANSS-30 for clinical and functional outcomes in first-episode psychosis: A 2-year follow-up in a Spanish cohort. Eur Neuropsychopharm. 2025; 95: 9-13. Article. IF: 8.1; D1*
- **López-Cuadrado T, Mortier P, Alonso J, Martínez-Alés G.** *Trends of non-lethal intentional self-harm and suicide in Spain 2018-2023: a nationwide registry-based study. Lancet Reg Health Eur. 2025; 58: 101467. Article. IF: 15.7; D1*
- **López-Morinigo JD, Fiorillo A, Dom G, Arango C.** *Mental health status of the European population and its determinants: A cross-national comparison study. Eur Psychiat. 2025; 68(1): e103. Article. IF: 7.9; D1*
- **Mathalon DH, Nicholas S, Roach BJ, Billah T, Lavoie S, Whitford T, Hamilton HK, Addamo L, Anohkin A, Bekinschtein T, Belger A, Buccilli K, Cahill J, Carrion RE, Damiani S, Dzafic I, Ebdrup BH, Izyurov I, Jarcho J, Jenni R, Jo A, Kerins S, Lee CRC, Martin EA, Mayol-Troncoso R, Niznikiewicz MA, Parvaz M, Pogarell O, Prieto-Montalvo J, Rabin R, Roalf DR, Rogers J, Salisbury DF, Shaik R, Shankman S, Stevens MC, Suen YN, Swann NC, Tang XC, Thompson JL, Tso I, Wenzel J, Zhou JH, Addington J, Alameda L, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Castillo-Passi RI, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Díaz-Caneja CM, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthoj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Mittal VA, Nordentoft M, Pearlson GD, Pérez J, Perkins DO, Powers AR, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Upthegrove R, Verma SK, Wang JJ, Wolf DH, Zhang TH, Bouix S, Pasternak O, Cho KIK, Coleman MJ, Dwyer D, Nunez A, Tamayo Z, Wood SJ, Kahn RS, Kane JM, Mcgorry PD, Bearden CE, Nelson B, Woods SW, Shenton ME, Light GA.** *The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures. Schizophrenia (Heidelb). 2025; 11(1): 85. Article. IF: 4.5; Q1*
- **Medel V, Alliende LM, Bethlehem R, Seidlitz J, Ringlein G, Arango C, Arnatkeviciute A, Asmal L, Bellgrove M, Benegal V, Bernardo M, Billeke P, Bosch-Bayard J, Bressan R, Busatto G, Castro M, Chaim-Avancini T, Costanzi M, Czepielewski L, Dazzan P, de la Fuente-sandoval C, Díaz-Caneja CM, Di Forti M, Díaz-Zuluaga AM, Du Plessis S, Duran F, Fittipaldi S, Fornito A, Freimer N, Gadelha A, Gama C, Garani R, García-Rizo C, Campo CG, González-Valderrama A, Guinjoan S, Holla B, Ibañez A, Ivanovic D, Jackowski A, Leon-Ortiz P, Lochner C, López-Jaramillo C, Luckhoff H, Massuda R, Mcguire P, Miyata J, Mizrahi R, Murray R, Ozerdem A, Pan PD, Parellada M, Phahladira L, Ramirez-Mahaluf JP, Reckziegel R, Marques TR, Reyes-Madrigal F, Roos A, Rosa P, Salum G, Scheffler F, Schumann G, Serpa M, Stein DJ, Tepper A, Tiego J, Ueno T, Undurraga J, Undurraga EA, Valdes-Sosa P, Valli I, Villarreal M, Winton-Brown TT, Yalin N, Zamorano F, Zanetti M, Winkler AM, Evans-Lacko S, Crossley NA.** *Human development, inequality, and their associations with brain structure across 29 countries. Eur Psychiat. 2025; 68(1): e100. Article. IF: 7.9; D1*
- **Moreno C, Abregú-Crespo R, Mayoral M.** *Childhood trauma: the elephant in the room in child and adolescent psychiatry. Eur Child Adoles Psy. 2025; 34(9): 2627-9. Editorial Material. IF: 4.4; Q1*
- **Olazagoitia-Garmendia A, Rojas-Márquez H, Trobisch T, Moreno-Castro C, Etxebarria AR, Mentxaka J, Tripathi A, Yang BB, Ruiz IM, Anguita J, Meana JJ, Ding YL, Dutta R, Schirmer L, Igoillo-Esteve M, Santin I, Castellanos-Rubio A.** *An inflammation-associated lncRNA induces neuronal damage via mitochondrial dysfunction. Mol Ther Nucleic Acids. 2025; 36(2): 102533. Article. IF: 6.5; Q1*
- **Palagini L, Arango C, Bassetti CLA, Bastien C, Geoffroy PA, Elder G, Ellis J, Hedner J, Khullar A, Nobili L, Partinen M, Saletu M, Vieta E, Morin CM, Riemann D, Strambi LF, Fiorillo A.** *The need to prioritize insomnia disorder in public health agendas: a wakeup call position paper from European and Canadian experts in sleep and mental health. Sleep Med. 2025; 135: 106763. Article. IF: 4.1; Q1*
- **Pemau A, de la Torre-luque A, Marín-Martín C, Díaz-Marsa M, Andreo-Jover J, Ayad-Ahmed W, Ortiz MFB, Bobes-Bascarán MT, Canal-Rivero M, García IC, Cebrià AI, Crespo-Facorro B, Boti MA, Elices M, González-Pinto A, Grande I, Jiménez-Treviño L, Palao DJ, Palao-Tarrero A, Pérez-Guerra C, Roberto N, Veguilla MR, Sáiz PA, SURVIVE Consortium, Pérez V.** *Symptomatic networks in suicide attempt and reattempt: Relevance of psychiatric comorbidity. Eur Psychiat. 2025; 68(1): e4. Article. IF: 7.9; D1*
- **Penzel N, Polosecki P, Addington J, Arango C, Asgari-Targhi A, Billah T, Bouix S, Calkins ME, Campbell DE, Cannon TD, Castro E, Cho KIK, Coleman MJ, Corcoran CM, Dwyer D, Frangou S, Fusar-Poli P, Glynn RJ, Haidar A, Harms MP, Jacobs GR, Kambeitz J, Kapur T, Kelly SM, Koutsouleris N, Abhinandan KR, Kucukemiroglu S, Kwon JS, Lewandowski KE, Li QS, Mantua V, Mathalon DH, Mittal VA, Nicholas S, Pandina GJ, Perkins DO, Potter A, Reichenberg A, Reinen J, Sand MS, Seitz-Holland J, Shah JL, Srinivasan V, Srivastava A, Stone WS, Torous J, Vangel MG, Wang JJ, Wolff P, Yao BE, Anticevic A, Wolf DH, Zhu H, Bearden CE, McGorry PD, Nelson B, Kane JM, Woods SW, Kahn RS, Shenton ME, Cecchi G, Pasternak O.** *Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program. Schizophrenia (Heidelb). 2025; 11(1): 53. Article. IF: 4.5; Q1*
- **Petri-Romao P, Martínez-Alés G, Martinez-Morata I, Moreno-Küstner B, Fernández-Jiménez E, Hecker I, Melchior M, Mittendorfer-Rutz E, Sijbrandij M, Walter H, Witteveen AB, Ayuso-Mateos JL, Bravo-Ortiz**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

MF, Kalisch R, Puhlmann LMC, Mediavilla R. *Resilience changes and occupational resilience factors among healthcare workers during and after the COVID-19 pandemic: A 2-year prospective cohort study. Sci Rep-Uk. 2025; 15(1): 29263. Article. IF: 4.9; Q1*

- **Petri-Romao P, Mediavilla R, Restrepo-Henao A, Puhlmann LMC, Zerban M, Ahrens KF, Barbui C, Basten U, Bayon C, Chmitorz A, Felez-Nobrega M, Kollmann B, Lieb K, McDaid D, McGreevy KR, Melchior M, Muñoz-Sanjosé A, Neumann RJ, Park AL, Plichta MM, Purgato M, Reif A, Schenk C, Schick A, Sebastian A, Sijbrandij M, Smith P, Tüscher O, Wessa M, Witteveen AB, Yuen KSL, Haro JM, Ayuso-Mateos JL, Kalisch R.** *Positive appraisal style predicts long-term stress resilience and mediates the effect of a pro-resilience intervention. Nat Commun. 2025; 16(1): 10269. Article. IF: 18.1; D1*
- **Pujadas ER, Díaz-Caneja CM, Stevanovic D, Quintero MF, Martin-Isla C, Hernández-González J, Atehortúa A, Lazrak N, Pries L, Delespaul P, Camacho M, Gülöksüz S, Rutten BPF, Lekadir K.** *Longitudinal prediction of mental health outcomes in vulnerable youth using machine learning. Cogn Comput. 2025; 17(5): -152. Article. IF: 7.4; D1*
- **Rodríguez-Rodríguez GJ, Martínez-Alés G, López-Cuadrado T.** *Suicide Among Older People in Spain: The role of sex and urbanicity. Int J Geriatr Psych. 2025; 40(3): e70071. Article. IF: 3.3; Q2*
- **Saracaydin G, van Rooij D, Kleine-Deters R, Messchendorp M, Naaijen J, Penzol MJ, Rosa M, Aggensteiner PM, Baumeister S, Holz N, Banaschewski T, Saam M, Schulze UME, Sethi A, Craig M, Castro-Fornieles J, Arango C, Walitza S, Werhahn J, Brandeis D, Franke B, Ruisch IH, Buitelaar JK, Dietrich A, Hoekstra PJ.** *Disentangling the neural underpinnings of response inhibition in disruptive behavior and co-occurring ADHD. Eur Child Adoles Psy. 2025; 34(7): 2253-67. Article. IF: 4.4; Q1*
- **Schalk L, Sethi A, Saam MC, Flamarique I, Naaijen J, Dietrich A, Hoekstra PJ, Banaschewski T, Aggensteiner PM, Holz N, Baumeister S, Borràs R, Rosa-Justicia M, Santosh P, Sagar-Ouriaghli I, Arango C, Penzol MJ, Brandeis D, Walitza S, Werhahn JE, Franke B, Glennon JC, Zwiers MP, Schulze UME, Castro-Fornieles J, Buitelaar JK, Craig MC.** *White matter microstructure of the cingulum bundle and the uncinate fasciculus in primary and secondary callous-unemotional traits. Eur Child Adoles Psy. 2025; 34(12): 4035-51. Article. IF: 4.4; Q1*
- **Segura AG, Verdolini N, Valli I, García-Rizo C, Díaz-Caneja CM, Vieta E, Mezquida G, Lobo A, González-Pinto A, Andreu-Bernabeu A, Roldan A, Martinez-Aran A, Baeza I, Mane A, Labad J, Müller DJ, Guasch-Capella N, Bernardo M, Mas S, Bioque GM, González J, Andrés P, Cavone V, Corripio I, Duque A, Mar-Barrutia L, Marin J, De-la-Camara C, Vaquero-Puyuelo D, Rivero O, Fabra MJE, Trabsa A, Legido T, Forte MF, Serra-Navarro M, de la Serna H, Castro-Fornielles J, Contreras F, García-Portilla MP, González-Blanco L, Echevarría RS, Rabadán AZ, Rodríguez-Jimenez R, Martínez-Gras I, Usall J, Barajas A, Sarro S, Pomarol-Clotet E, Ibañez A, Cuesta MJ.** *Polygenic risk score of glycemic homeostasis, Type 2 Diabetes Mellitus and glycemic components in first episode psychosis. Schizophr Res. 2025; 285: 265-75. Article. IF: 3.7; Q2*
- **Sideli L, Aas M, Alameda L, Trotta G, La Barbera D, La Cascia C, Ferraro L, Velthorst E, Tripoli G, Schimmenti A, Fontana A, Quattrone D, Gayer-Anderson C, Rodríguez V, Spinazzola E, Stilo S, Seminerio F, Sartorio C, Marrazzo G, Lasalvia A, Tosato S, Tarricone I, D'Andrea G, Arango C, Arrojo M, Bernardo M, Bobes J, Sanjuán J, Santos JL, Menezes PR, Del-Ben CM, Jongsma HE, Jones PB, Kirkbride JB, Llorca P, Tortelli A, Pignon B, de Haan L, Selten J, Van Os J, Rutten BP, Di Forti M, Murray RM, Morgan C, Fisher HL.** *Interplay between childhood maltreatment, subclinical post-traumatic stress symptoms, and IQ: Findings from the EU-GEI Multicentre Case-Control Study. Early Interv Psychia. 2025; 19(8): e70079. Article. IF: 2.3; Q3*
- **Stringaris A, Burman C, Delpech R, Uher R, Bhudia D, Miliou D, Rokas IM, Kyriakopoulos M, Foulkes L, Moreno C, Cortese S, Lewis G, Krebs G.** *Comparing apples and oranges in youth depression treatments? A quantitative critique of the evidence base and guidelines. BMJ Ment Health. 2025; 28(1): e301162. Article. IF: 6.6; D1*
- **Szmulewicz AG, Martinez-Alés G, Logan R, Joober R, Ferrara M, Kelly C, Fredrikson D, Thorpe LE, Conderino S, Díaz-Caneja CM, Srihari V, Yatham LN, Sarpal DK, Shinn AK, Arango C, Shah JL, Öngür D, Hernán MA.** *Comparative effectiveness of long-acting injectable versus oral antipsychotic medication after a first episode of psychosis. Nat Ment Health. 2025; 3(4): 1EJ8M. Article. IF: 9.3; D1*
- **van de Burgt NA, Kulsvehagen L, Mané-Damas M, Lutz L, Lecourt AC, Monserrat C, Vinke AM, Küçükali CI, Zong SH, Hoffmann C, González-Vioque E, Arango C, Leibold NK, Losen M, Molenaar PC, Tüzün E, van Beveren NJM, Mané A, Rouhl RPW, van Amelsvoort TAMJ, Pröbstel AK, Martinez-Martinez P.** *Autoantibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with psychotic symptoms. Front Neurol. 2025; 16: 1593042. Article. IF: 3.3; Q2*
- **Vieta E, Ahmed N, Arango C, Cleare AJ, Demyttenaere K, Dold M, Ito T, Kambarov Y, Krüger S, Llorca PM, Mcintyre RS, Sani G, von Holt C, Rive B.** *Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study. Eur Neuropsychopharm. 2025; 93: 29-39. Article. IF: 8.1; D1*

Research projects

- **Arango C.** Ambiente y genes en esquizofrenia-grupos de investigación de la comunidad de Madrid (AGES-CM 3-CM) (B2022/BMD-7216). Biomedicina-Comunidad de Madrid. 2023-2026. Managment centre: HGUGM
- **Arango C.** Estudio de coste-efectividad del programa de coordinación y enlace en salud mental infanto-juvenil para centros escolares (2024-DON004 FAK). Fundación Alicia Koplowitz. 2023-2026. Managment centre: HGUGM
- **Arango C.** Interacciones genes-ambiente en las trayectorias de salud mental de los jóvenes (PI22/01824). ISCIII. 2023-2025. Managment centre: HGUGM
- **Arango C.** The impact of social isolation on aging health in schizophrenia (loneliness-NIH) (NIH-2022/Aging). US National Institutes of Health (NIH). 2022-2027. Managment centre: HGUGM
- **Bravo Ortiz MF.** Ambiente y genes en esquizofrenia. (S2022/BMD-7216 AGES 3-CM). CM. 2023-2026. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Apoyo a investigadores que han participado como mentores. (Dr. Luis Alvarez 2023). Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2024-2025. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Contrato garantía juvenil ayudante de investigación. (PEJ-2021-AI/SAL-22352). CM. 2023-2024. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Estudio De Coste Efectividad De Un Programa De Hospitalización Domiciliaria De Salud Mental En Infancia Y Adolescencia En Dos Áreas De Influencia De Dos Hospitales De Madrid (Hospital Universitario La Paz Y Hospital Universitario Príncipe De Asturias). Fundación Nemesio Diez. 2024-Ongoing. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Estudio longitudinal de una cohorte representativa: superando la heterogeneidad clínica y biológica en primeros episodios psicóticos. (PI20/01113). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Impacto de la pandemia de COVID-19 en la salud mental de trabajadores en dispositivos sanitarios. Estudio internacional multicéntrico: the COVID-19 Heroes Study. (PI-4099-BRAVO ORTIZ). Sociedad Española de Psiquiatría. 2020-Ongoing. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Improving the Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns resulting from the COVID-19 Pandemic. (RESPOND). UE. 2020-2024. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Programa de enlace de salud mental y educación (CELSO ARANGO-MMA 2024). Fundación Mutua Madrileña. 2024-Ongoing. Managment centre: FIBHULP
- **Fernández Jiménez E.** Identificación de necesidades pre- y post-quirúrgica y evolución

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



neuropsicológica y biopsicosocial en población infantojuvenil sometida a cirugía de trasplante de órgano sólido y pectus excavatum. proyecto psycmajorsurgeries. (PI-5223/2022014). Fundación Alicia Koplowitz. 2022-Ongoing. Managment centre: FIBHULP

- **Fernández Jiménez E.** Marcadores neurocognitivos y perfil psicológico en población infantil, adolescente y en adultos jóvenes receptores de terapia con células CAR-T y trasplante hematopoyético: Estudio observacional comparativo. (Dr. Luis Alvarez 2023). FIBHULP. 2023-2024. Managment centre: FIBHULP
- **Fernández Jiménez E.** Marcadores neurocognitivos y perfil psicológico en población infantil, adolescente y en adultos jóvenes receptores de terapia con células car-t y trasplante hematopoyético: estudio observacional comparativo. (PI-5562/2023.063). Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2022-Ongoing. Managment centre: FIBHULP
- **Fernández Jiménez E.** PsyCARTkids: impacto bio-psicológico del entrenamiento cognitivo y mindfulness en menores tras terapia car-t, trasplante hematopoyético o quimioterapia: estudio de métodos mixtos y ensayo controlado-aleatorizado (PI23/00179). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Martínez Díaz-Caneja C.** Bridging Gaps in Mental Health Support: A Comprehensive European Strategy YOUTHreach (101156514-2). HORIZON-HLTH-2024-DISEASE-03-two-stage. 2025-2030. Managment centre: FIBHULP
- **Martínez Díaz-Caneja C.** Estudio piloto de implementación de una herramienta de cribado para la prevención, diagnóstico y tratamiento de pacientes con un trastorno psiquiátrico del neurodesarrollo: utilización del síndrome deleción 22q11.2 (PMP22/00088). Medicina Personalizada y de Precisión. Carlos III, Ministerio de Ciencia, Innovación y Universidades. 2023-2025. Managment centre: HGUGM
- **Martínez Díaz-Caneja C.** Hacia una intervención estratificada en psiquiatría: Predicción de trayectorias de riesgo y resiliencia para la salud mental en una muestra transdiagnóstica de jóvenes (proyecto PREMY) (PI23/00625). ISCIII. 2024-2026. Managment centre: HGUGM
- **Martínez Díaz-Caneja C.** Youth-GEMs:Gene Environment interactions in Mental health trajectories of Youth (HORIZON-HLTH-2021-STAYHLTH-01) Comisión Europea. 2022-2027. Managment centre: HGUGM
- **Moreno C.** Bootstrap: Boosting Societal Adaptation and Mental Health in a Rapidly Digitalizing, Post-Pandemic Europe (HE BOOTSTRAP 101080238-1). HORIZON-HLTH-2021-STAYHLTH-01-02. 2023-2028. Managment centre: HGUGM
- **Moreno C.** Mecanismos etiofisiopatológicos implicados en la desregulación emocional en depresión y riesgo de suicidio en adolescentes (FFA24/02). Fundación Familia Alonso. 2024-2026. Managment centre: HGUGM
- **Moreno C.** Psych-STRATA: Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness (HORIZON-HLTH-2021-STAYHLTH-01-02). Comisión Europea. 2022-2027. Managment centre: HGUGM
- **Muñoz San José A.** Hacia una intervención estratificada en psiquiatría: predicción de trayectorias de riesgo y resiliencia para la salud mental en una muestra transdiagnóstica de jóvenes (PI23/00380). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Nocete Navarro L.** Fostering and Strengthening Approaches to Reducing Coercion in European Mental Health Services (CA19133). 2024-Ongoing. Managment centre: FIBHULP
- **Palao Tarrera A.** Intensificación de la actividad investigadora de investigadores participantes del programa mentor. FIBHULP. 2023-2024. Managment centre: FIBHULP
- **Palao Tarrera A.** SMARTomicS: prevención de la conducta suicida mediante intervenciones terapéuticas guiadas por fenotipo digital y farmacogenética (PMP24/00026). Medicina Personalizada y de Precisión. Carlos III, Ministerio de Ciencia, Innovación y Universidades. 2025-2026. Managment centre: FIBHULP
- **Palao Tarrera A.** SURVIVE 2: un estudio de cohorte extendida para investigar la conducta suicida en España y la eficacia de estrategias de prevención secundaria (PI23/01469). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Rodríguez Vega B.** Prevención e intervención en suicidio (SURVIVE): estudio de cohorte y ensayos clínicos controlados anidados de programas de prevención secundaria para intentos de suicidio. (PI19/00941). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Rodríguez Vega B.** Traducción y validación de los instrumentos reflective functioning questionnaire e inventary of personality onganization. Fundación Vasca de Innovacion e Investigación Sanitarias. 2018-Ongoing. Managment centre: FIBHULP
- **Villanueva Peña R.** A Randomnized, Double-blind, Multicenter, Parallel-group, Placebo-controlled. Study to evaluated the efficacy, safety, and tolerability of aticaprant 10 mg as adjunctive therapy in adult participants with major depressive disorder (MDD) with moderated-to-severe anhedonia and inadequate response to current antidepressant therapy protocol 67953964MDD3001 VENTURA-1;PAHASE 3. Janssen Pharmaceutica. 2023-2024. Managment centre: FIBHULP

Clinical Trials

- **Villanueva Peña R.** A two-part multicenter, double-blind, randomized placebo-controlled study to evaluate efficacy and safety and the maintenance of effect of 20-mg seltorexant as adjunctive therapy to antidepressants in adult and elderly patients with major depressive disorder with insomnia symptoms.
  Type/Phase: III
  Sponsored by: Icon Clinical Research Limited.
  Signature date: 13/05/2025
- **"Villanueva Peña R.** A cohort, non-interventional, prospective, real-world study of functional remission in trd patients treated with esketamine nasal spray estudio de cohortes, no intervencionista, prospectivo, de practica real para evaluar la remisión funcional en pacientes con trd tratados con esketamina intranasal.
  Type/Phase: EOm prospectivo
  Sponsored by: Janssen-Cilag España, S.A.
  Signature date: 05/03/2025"

Patents and Trademarks

Rodríguez Vega B, authors; FIBHULP, assignee. Brand name: En calma; ESM 3.695.071; 2017 December 12.

Rodríguez Vega B, Mediavilla Torres R, Bravo Ortiz MF, Muñoz San José A, Bayón Pérez C, Lahera Forteza G, Palao Tarrero A. authors; FIBHULP, assignee. Brand name: SocialMind; ESM 3.748.550; 2018 December 17.